Pfizer to pay nearly $60M over kickbacks for migraine drug once promoted by Lady Gaga
The pharmaceutical giant Pfizer will pay nearly $60 million to resolve charges that a company it acquired paid kickbacks so that physicians would prescribe a specific migraine drug to patients.
Pfizer pays close to $60 million to resolve kickback allegations
Pfizer subsidiary Biohaven allegedly gave physicians speaker honoraria and meals at high-end restaurants to induce them to prescribe Nurtec.
Pfizer shells out nearly $60M to resolve Nurtec kickback claims inherited in Biohaven buyout
Over the years, the U.S. Department of Justice (DOJ) has taken a host of drugmakers to task over alleged kickback payments intended to boost prescriptions. | Pfizer—which purchased Biohaven for $11.6 billion in 2022—is committing more than $59.
Pfizer to pay $59.7 million over kickbacks for migraine drug
Pfizer will pay $59.7 million to resolve charges that a company it acquired defrauded Medicare and other healthcare programs by paying kickbacks so doctors would prescribe the migraine drug Nurtec ODT,
Pfizer to Pay $60 Million in Kickback, False Claims Settlement
Pfizer will pay $60 million to settle allegations that one of its subsidiaries incentivized healthcare providers to prescribe one of its drugs, resulting in the submission of false claims to federal healthcare programs.
Pfizer Settles $59.7M Medicare Kickback Case Over Biohaven Practices
Pfizer (NYSE:PFE) has agreed to pay $59.7 million to resolve allegations that Biohaven Pharmaceuticals, acquired by Pfizer in October 2022, defrauded Medicare and other healthcare programs by offering kickbacks to
Pfizer to pay $60 million to settle claims that Biohaven paid kickbacks to doctors
The alleged violations occurred before Pfizer bought Biohaven and its migraine treatment three years ago for $11.6 billion.
Pfizer settles Biohaven kickback case with DOJ for $60M
Pfizer (NYSE:PFE) has agreed to pay nearly $60M to resolve allegations that its Biohaven unit paid kickbacks to physicians to induce prescriptions for its migraine drug Nurtec ODT. The U.S. Department of Justice alleged Biohaven knowingly caused the submission of false claims to government programs such as Medicare through kickbacks made between
NYC Project to Convert Former Pfizer Headquarters Lands $135 Million Loan
The effort to convert Pfizer Inc.’s former New York headquarters into residences secured financing to help developers forge ...
Crain's New York4h
Project to convert former Pfizer HQ into housing lands $135M loan
David Werner Real Estate Investments and Metro Loft are planning to turn the 33-story tower and neighboring building into ...
BioSpace1d
Pfizer Gets Breather From Starboard’s Ongoing Assault
Starboard last year took a $1 billion stake in Pfizer, looking to turn the pharma around after alleged severe shortcomings by ...
Pfizer Dodges Challenge to Its Board in Fight With Starboard
Pfizer Inc. got a reprieve — at least for now — in its battle with activist investor Starboard Value LP, according to people ...
FiercePharma2d
Pfizer avoids board nominations from Starboard as proxy fight rolls on: Bloomberg
Following a tough opening salvo from Starboard Value last fall, Pfizer is getting a chance to catch its breath in the ...
Pfizer Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by ...
Pharmaceutical Technology on MSN2d
Pfizer settles Biohaven kickback claims case for $59.7m
Biohaven, acquired by Pfizer in 2022, allegedly took doctors to high-end restaurants and paid speaker honoraria for ...
Pfizer Q4 Earnings Preview: 5 Critical Business Issues To Consider
Financial analysis of Pfizer Inc. stock ahead of its earnings release. PFE faces significant headwinds from patent expiries, click for my updated look at the stock.
What's Going On With Pfizer Stock Monday?
Pfizer Inc (NYSE:PFE) shares are trading higher Monday. Some of the optimism may be surrounding activist Starboard Value's ...